- InterView
- Immunotherapy for early lung cancer was used
- by Jun 29, 2023 05:56am
- As immuno-anticancer drugs can be used in early lung cancer, the prognosis of patients is improving. Unlike before, when chemotherapy and concurrent chemoradiation were all, it is evaluated that the number of cases of 'complete pathological remission' has increased. Opdivo was approved by the Ministry of Food and Drug Safety in October of last y
- Policy
- New oral ulcerative colitis drug Zeposia approved
- by Lee, Hye-Kyung Jun 28, 2023 05:53am
- BMS Korea’s new ulcerative colitis treatment ‘Zeposia Cap (ozanimod)’ seems to have been granted marketing authorization for its effectiveness in broadening the treatment option for patients with ulcerative colitis despite the small number of clinical trial subjects. The recent minutes of the Central Pharmaceutical Affairs Council that
- Company
- Imjudo, the No. 8 immune anti-cancer drug, landed
- by Jun 28, 2023 05:53am
- The 8th and 2nd immuno-anticancer drug with CTLA-4 inhibitory mechanism has appeared in Korea. After more than 10 years of development, AstraZeneca created the first immuno-oncology + immuno-oncology combination option in liver cancer. According to the pharmaceutical industry on the 26th, the Ministry of Food and Drug Safety recently granted
- Company
- Generic for Paxlovid PQ certification for 1 year
- by Jun 28, 2023 05:53am
- Among the 36 pharmaceutical companies that have introduced Paxlovid's generic license for an edible COVID-19 treatment, some companies are attempting World Health Organization (WHO) pre-qualification (PQ) certification. Each pharmaceutical company is expected to obtain PQ certification even after the COVID-19 emergency is lifted and supply me
- Company
- Seize the promising target Claudin market
- by Jun 28, 2023 05:53am
- Claudin 18.2 (CLDN18.2) is emerging as a new alternative for gastric cancer with a poor prognosis, and a development boom is brewing among global pharmaceutical companies. Various new drugs such as cell therapy drugs and bispecific antibodies have been put to the test in order to preoccupy this market, which is a communist communist country.
- Policy
- The share of drug spending was about 23 trillion won
- by Lee, Tak-Sun Jun 28, 2023 05:53am
- Last year, the share of health insurance drug expenses was 23%, the lowest level in the past five years. Although drug costs themselves are steadily increasing, the rate of increase in total medical costs is much higher, indicating that the proportion of drug costs is continuously declining. According to the 'Current Status of Claims for Reim
- Company
- SK bioscience collaborates with the Doherty Institute
- by Jun 28, 2023 05:53am
- SK bioscience announced on the 27th that it had signed a research cooperation agreement with the Peter Doherty Institute for Infection and Immunity in Australia for global influenza prevention and response. The Peter Doherty Institute for Infection and Immunity is an infectious disease research institute affiliated with the University of Melb
- Company
- Reimb progress of 2 NMOSD drugs receive attention in 2H
- by Eo, Yun-Ho Jun 28, 2023 05:52am
- Whether the two optic nerve sclerosis drugs that have remained non-reimbursed for a long time in Korea will be reimbursed this time is receiving attention. According to industry sources, discussions are ongoing to introduce the agenda on reimbursing the neuromyelitis optica spectrum disorder (NMOSD) indication of ’Soliris (eculizumab)’
- Policy
- 4 Vemlidy latecomers reimbursed in Korea
- by Lee, Tak-Sun Jun 27, 2023 05:48am
- Four more Vemlidy latecomers will be entering the market. Currently, only 3 products by Dong-A ST, Daewoong Pharmaceutical, and Chong Kun Dang are available in the market. Its original drug is Gilead Science Korea’s Vemlidy Tab. According to industry sources on the 25th, Samjin Pharm, Korea Hutex Pharma, Samil Pharm, and Dongkook Pharmac
- Company
- B-cell lymphoma drug Polivy applies for reimb again
- by Eo, Yun-Ho Jun 27, 2023 05:47am
- The B-cell lymphoma drug ‘Polivy’ is reattempting to receive reimbursement in Korea. This time, the company applied for Polivy’s reimbursement with a different indication. According to industry sources, Roche Korea submitted an application for the reimbursement of its Diffuse Large B-Cell Lymphoma (DLBCL) treatment Polivy (polatuzumab
